Institutional Ownership
Xeris Biopharma Holdings Inc
CUSIP 98422E103COMXERSQ1 2026
13D / 13G Filings
10
Schedule 13D/13G on record
Beneficial Filers
7
Distinct reporting persons
Largest Stake
8.2%
Max % of class reported
Institutional Holders
235
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
10 filings · latest Jan 30, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Jan 30, 2026 | The Vanguard Group | 13G/A | 6.7% | 11.19M | SEC |
| 2 | Feb 13, 2024 | Vanguard Group Inc | 13G | 5.1% | 7.09M | SEC |
| 3 | Feb 13, 2024 | Stonepine Capital Management, LLC | 13G/A | 4.3% | 5.94M | SEC |
| 4 | Jan 26, 2024 | Blackrock Inc. | 13G | 7.2% | 10.01M | SEC |
| 5 | Feb 14, 2023 | Caxton Corp | 13G/A | 4.4% | 5.97M | SEC |
| 6 | Feb 13, 2023 | Stonepine Capital Management, LLC | 13G/A | 8.2% | 11.20M | SEC |
| 7 | Feb 14, 2022 | Sessa Capital (Master), L.P. | 13G/A | 2.4% | 3.26M | SEC |
| 8 | Feb 11, 2022 | Flynn James E | 13G/A | 2.0% | 2.61M | SEC |
| 9 | Jan 14, 2022 | Stonepine Capital Management, LLC | 13G | 5.2% | 6.49M | SEC |
| 10 | Jan 5, 2022 | Caxton Corp | 13G | 5.7% | 7.83M | SEC |
Top Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Blackrock, Inc. | 12.95M | $75.09M |
| 2 | D. E. Shaw & Co., Inc. | 7.79M | $45.18M |
| 3 | Vanguard Capital Management LLC | 6.98M | $40.49M |
| 4 | State Street Corp | 4.66M | $27.02M |
| 5 | Geode Capital Management, LLC | 4.29M | $24.89M |
| 6 | Qube Research & Technologies Ltd | 4.11M | $23.86M |
| 7 | Rosalind Advisors, Inc. | 3.23M | $18.74M |
| 8 | Nuveen, LLC | 2.92M | $16.92M |
| 9 | Vanguard Portfolio Management LLC | 2.67M | $15.46M |
| 10 | Morgan Stanley | 2.57M | $14.92M |